Moonwalk Biosciences closed a $70 million Series B funding round to advance its lead adipose-targeted RNA interference candidate, MW101, into first-in-human clinical trials by late 2027. Led by Alpha Wave and YK Bioventures, the financing will expand the South San Francisco biotech firm’s epigenetic and multi-omics discovery platform.
The fresh capital infusion positions Moonwalk Biosciences to accelerate its pipeline of tissue-targeted small interfering RNA (siRNA) therapeutics. Obesity and cardiometabolic diseases currently present healthcare burdens, driving the demand for more precise therapeutics that avoid traditional drawbacks associated with older drug classes.
In Plain English: The Clinical Takeaway
- What is RNAi? RNA interference (RNAi) is a biological process where small snippets of RNA are used to turn off or “silence” specific genes before they can produce disease-causing proteins.
- Targeting Fat Tissue: Instead of affecting the entire body, Moonwalk’s delivery mechanism zeroes in specifically on adipose (fat) tissue, which aims to reduce off-target side effects.
- Preserving Muscle Mass: The experimental pipeline is engineered to modulate non-incretin pathways—mechanisms that do not rely on gut hormones like GLP-1—while protecting lean muscle mass during weight loss.
The Science of Epigenetic and Tissue-Targeted Modulation
Led by CEO Alex Aravanis, M.D., Ph.D., Moonwalk Biosciences operates at the intersection of human genetics, epigenomics, and advanced tissue-targeting chemistry. Traditional biologic and small-molecule interventions often hit multiple organ systems simultaneously, leading to complex side-effect profiles. By contrast, precision siRNA platforms allow researchers to modulate novel, non-incretin pathways underlying obesity directly at the cellular level.
According to FinSMEs reporting on the August 2026 financing round, the $70 million Series B was co-led by Alpha Wave and YK Bioventures. Additional participation came from established life sciences backers, including Eli Lilly and Company, Gaorong Ventures, ARCH Venture Partners, Khosla Ventures, and Future Ventures. This broad syndicate of institutional and strategic investors underscores the industry-wide push toward next-generation metabolic therapeutics that go beyond standard incretin receptor agonists.
Regulatory Horizons and Global Health Implications
Clinical trials evaluating adipose-targeted siRNA will require rigorous Phase I safety assessments in healthy volunteers before advancing to patient populations.
| Development Metric | Clinical Detail |
|---|---|
| Lead Candidate | MW101 (Adipose-targeted RNAi) |
| Financing Secured | $70 Million Series B |
| Lead Investors | Alpha Wave and YK Bioventures |
| Projected Clinic Entry | Late 2027 |
Treatments that preserve lean muscle mass while targeting underlying epigenetic drivers could fulfill a major unmet clinical need. However, clinical validation through double-blind, placebo-controlled trials remains essential to prove long-term safety and efficacy.
Contraindications & When to Consult a Doctor
Because MW101 remains in the pre-clinical development phase, human administration outside of a controlled clinical trial setting is unavailable. Patients managing obesity or cardiometabolic conditions should not seek experimental RNAi treatments outside of approved trial protocols.
Consult a qualified healthcare provider or endocrinologist before making any changes to an existing weight management regimen or metabolic disease treatment plan. Seek immediate medical attention if you experience severe adverse reactions, unexpected gastrointestinal distress, or systemic symptoms while taking prescribed therapeutics.
Conclusion
Moonwalk Biosciences’ $70 million Series B financing highlights the continued investor confidence in advanced genetic and epigenetic therapeutics. By focusing on adipose-targeted RNAi, the company aims to offer a refined approach to metabolic disease. Translating these platform capabilities into proven clinical outcomes remains the critical next step for researchers and clinicians alike.
References
- FinSMEs. “Moonwalk Biosciences Raises $70M in Series B Financing.” Published August 9, 2026.
- "RNA Interference (RNAi): Biology, Mechanism, and Clinical Applications." PubMed Central.
- U.S. Food and Drug Administration (FDA). “Guidance for Industry: Nucleic Acid Based Therapeutics.” Regulatory Framework.
Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a licensed physician for any health-related concerns.
